EuroPCR 2023: Late-Breaking Science Video Collection
Published: 18 May 2023
-
Views:
1844
-
Likes:
7
-
Views:
1844
-
Likes:
7
-
Up Next -
6m 7sPart 1 | Session 5 EBC MAIN Three-Year Follow Up -
4m 59sPart 1 | Session 6 TVT Registry Analysis: TAVR in Patients with Cardiogenic Shock -
2m 35sPart 1 | Session 7 FAME III Three-Year Follow-Up
-
29m 21sPart 2 | Session 1 View from the Thoraxcenter: EuroPCR 23 Late-breaking Science Preview -
30m 41sPart 2 | Session 2 View from the Thoraxcenter: What's Hot at EuroPCR 23?
-
1m 5sPart 4 | Session 1 Dr Lim: Patient Care and Finding Your Passion -
1m 51s -
1m 45sPart 4 | Session 3 Dr Sorajja: Why He Chose Cardiovascular Medicine
-
5m 41sPart 1 | Session 1 EBC TWO Five Year Follow-Up: Two-Stent Vs One for Large Bifurcation Lesions Sandeep Arunothayaraj
-
6m 12sPart 1 | Session 2 BASILICA Vs Chimney-Stenting for TAVR-Related Coronary Obstruction Antonio Mangieri
-
3m 15sPart 1 | Session 3 DRAGONFLY-DMR: Safety and Effectiveness of Dragonfly TMVR System for Mitral Regurgitation D Scott Lim
Overview
Our regular review series View From the Thoraxcenter, hosted by Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) dives deep into the late-breaking trials of EuroPCR 2023, spotlighting the impactful data.
For short, concise coverage of the key data revealed, our accessible Expert Interviews were conducted with select faculty, focussing on the results, applicability and impact on future research.
Hear commentary on the practice-changing trials of EuroPCR 2023 from selected faculty in our Highlights Reviews.
Watch our Behind the Heart Series to hear more from the personal perspectives of the investigators behind the top trials of EuroPCR 2023.
More from this programme
Part 1
Expert Interviews
Short, concise overviews of the key data revealed at EuroPCR 2023, focussing on the results and impact on future research.
Part 2
View from the Thoraxcenter
In these concise episodes of View from the Thoraxcenter, Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) offer their thoughts on the top late-breaking trials that will be presented at EuroPCR 2023.
Part 3
Highlights Reviews
Commentary on the top late-breaking trials of EuroPCR 2023, as chosen by selected faculty.
Part 4
Behind the Heart
Watch our Behind the Heart series to learn more the personal perspectives from the investigators behind top trials in cardiovascular science.
About the episode
EuroPCR 23 - Dr Paul Sorajja (Abbott Northwestern Hospital, US) joined us to discuss the TRILUMINATE Pivotal study (NCT03904147).
The aim of this trial is to evaluate the safety and effectiveness of the tricuspid transcatheter edge-to-edge repair (TriClip, Abbott) in improving clinical outcomes for symptomatic patients with severe tricuspid regurgitation (TR) who have an intermediate or higher estimated risk for mortality or morbidity associated with tricuspid valve surgery. 700 patients were randomized into the TEER group and the medical therapy group. The data, presented at EuroPCR shows a reduction in tricuspid regurgitation in the device group as compared to control, and a marked increase in quality-of-life as measured using KCCQ scores.
Interview Questions:
- What are some of the unmet needs in patients with TR?
- What was the study design, patient population and outcome measures?
- What are the key findings to date?
- Were there any specific aspects of quality of life that showed the most notable improvement?
- What are the take-home messages for clinicians?
- What are the next steps? How do you see the future of TEER?
Recorded on-site at EuroPCR 2023, Paris.
Editors: Mirjam Boros, Jordan Rance
Video Specialists: Dan Brent, Oliver Miles
Faculty Biographies
Paul Sorajja
Director of the Center for Valve and Structural Heart Disease
Dr Paul Sorajja is an Interventional Cardiologist at the Minneapolis Heart Institute at Abbott Northwestern Hospital, where he is the Director of the Center for Valve and Structural Heart Disease.
Dr Sorajja's clinical practice specialises in interventional cardiology, with a focus on catheter-based therapy of valvular and structural heart disease. He was part of the team that performed the first transcatheter mitral valve replacement in the US for a patient with native mitral regurgitation in 2015, and has the highest worldwide experience with TMVR.
Dr Sorajja has published over 300 manuscripts and book chapters, with expertise in cardiac hemodynamics, clinical education, hypertrophic cardiomyopathy, and percutaneous therapy of structural heart disease.
Comments